Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
-
Publication number: 20140314776Abstract: The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof.Type: ApplicationFiled: December 11, 2012Publication date: October 23, 2014Inventors: Hua Zhu Ke, Min Liu, William V. Giannobile
-
Publication number: 20140314777Abstract: The present invention relates to murine monoclonal antibodies C, F and H which target major neutralizing epitopes of influenza H5 hemagglutinin of clade 2.3 and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using murine monoclonal antibodies C, F or H or active fragments thereof. The present invention additionally relates to methods and compositions for providing universal protection against H5 influenza viruses using murine monoclonal antibodies C, F or H or fragments thereof together with complementary murine monoclonal antibody or active fragments thereof. The present invention further relates to methods and compositions for the characterization and quantification of H5 expression using these murine monoclonal antibody or fragments thereof.Type: ApplicationFiled: January 12, 2012Publication date: October 23, 2014Applicant: TEMASEK LIFE SCIENCES LABORATORY LIMITEDInventors: Fang He, Jimmy Hwei-Sing Kwang
-
Publication number: 20140314775Abstract: Patients having a chronic or acute disease or acute condition, especially patients at the ICU (Intensive Care Unit) suffer from fluid imbalance. The present invention provides a medicament for regulating the fluid balance and/or improving the fluid balance of such patients. Subject matter of the present invention is an anti-Adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease or acute condition. The present invention also provides a method for regulating the fluid balance in a patient having a chronic or acute disease or acute condition. Subject matter of the present invention is an anti-Adrenomedullin ADM antibody or anti-ADM non-Ig scaffold or an anti-adrenomedullin antibody fragment for use in therapy of a chronic or acute disease or acute condition of a patient for the regulation of fluid balance.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Applicant: ADRENOMED AGInventor: Andreas Bergmann
-
Publication number: 20140314727Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desatorase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Surinder Pal Singh, Stanley Suresh Robert, Peter David Nichols, Susan Irene Ellis Blackburn, Xue-Rong Zhou, James Robertson Petrie, Allan Graham Green
-
Publication number: 20140314769Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: ApplicationFiled: December 17, 2013Publication date: October 23, 2014Inventors: Greg Elson, Olivier Leger
-
Publication number: 20140314744Abstract: Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin ?4 chain, e.g., an ?4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS.Type: ApplicationFiled: June 6, 2012Publication date: October 23, 2014Applicant: Neotope Biosciences LimitedInventors: Kenneth Flanagan, Jennifer Johnston, Theodore Yednock, Jeanne Baker
-
Publication number: 20140314772Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.Type: ApplicationFiled: June 27, 2014Publication date: October 23, 2014Inventors: Renfeng GUO, Niels Cristoph RIEDEMANN, Yan LI, Beifen SHEN
-
Patent number: 8865871Abstract: The instant invention provides antibodies which recognize new epitope tags. Related kits for detecting these epitope tags or fusion proteins having these epitope tags are also provided.Type: GrantFiled: November 22, 2011Date of Patent: October 21, 2014Assignee: The Rockefeller UniversityInventors: Chae Gyu Park, Ralph M. Steinman
-
Patent number: 8865171Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: July 7, 2005Date of Patent: October 21, 2014Assignee: The Henry M. Jackson Foundation For the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Publication number: 20140309404Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease.Type: ApplicationFiled: June 26, 2014Publication date: October 16, 2014Inventors: Neungseon Steven Seo, Stephanie Marie Eaton Truhlar
-
Publication number: 20140308271Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.Type: ApplicationFiled: January 2, 2014Publication date: October 16, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
-
Publication number: 20140308288Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: ApplicationFiled: March 12, 2014Publication date: October 16, 2014Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Publication number: 20140309292Abstract: The present application shows the relationship between variations in the amino acid sequence of histone proteins, more specifically the H3.3 protein, and proliferation-associated disorders. Herewith provided are predictive methods, commercial packages, therapeutic methods and screening methods based on this relationship.Type: ApplicationFiled: November 21, 2012Publication date: October 16, 2014Inventors: Nada Jabado, Stefan M. Pfister, Christoph Plass, Andrey Korshunov, Hendrik Witt, Dominik Sturm, David Jones, Peter Lichter, Elke Pfaff
-
Publication number: 20140308267Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises at least one E3 ligase recognition motif in the light chain, wherein said E3 ligase recognition motif is preferably a binding motif for the E3 ligase MDM2. The invention further pertains to polypeptides encoded by the polynucleotide of the invention as well as polypeptides comprising one or more amino acid substitutions. Further encompassed by the present invention are vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: ApplicationFiled: November 8, 2012Publication date: October 16, 2014Inventors: Michael Schmidt, Jurge Frevert, Fred Hofmann, Gerhard Groer
-
Publication number: 20140309172Abstract: The present disclosure identifies caspase-1/ICE as a therapeutic target for ?-synuclein associated diseases and disorders. Related methods and compositions are also provided.Type: ApplicationFiled: November 4, 2011Publication date: October 16, 2014Inventors: Dagmar Ringe, Gregory A. Petsko, Quyen Hoang
-
Publication number: 20140308302Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: ApplicationFiled: May 29, 2014Publication date: October 16, 2014Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Kodangattil R. SREEKUMAR
-
Publication number: 20140308685Abstract: The present invention provides a method and a reagent for measuring periostin contained in a sample with improved accuracy, a method for improving accuracy in measurement of periostin, and a method of testing for pulmonary fibrosis or interstitial pneumonia with improved accuracy. The antibody of the present invention binds to at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin or a cleavage product thereof. The method and the reagent for measuring periostin and the method for improving accuracy in periostin measurement of the present invention is characterized by detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin.Type: ApplicationFiled: September 6, 2012Publication date: October 16, 2014Applicants: SHINO-TEST CORPORATION, KURUME UNIVERSITY, SAGA UNIVERSITYInventors: Kenji Izuhara, Shoichiro Ohta, Kazuhiko Arima, Hiroshi Shiraishi, Shoichi Suzuki, Tomoaki Hoshino, Yoshinori Azuma, Junya Ono
-
Publication number: 20140308657Abstract: This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis). Also provided is an anti-SPIK antibody specific for an epitope comprising the first nine amino acids of intact SPIK.Type: ApplicationFiled: December 7, 2011Publication date: October 16, 2014Applicant: Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Xuanyong Lu, Timothy M. Block
-
Patent number: 8859240Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.Type: GrantFiled: June 2, 2009Date of Patent: October 14, 2014Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Frédéric Tangy, Philippe Despres, Chantal Combredet, Marie Pascale Frenkiel
-
Patent number: 8858940Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl12, Angptl13, Angptl14, Angptl15, Angptl16, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.Type: GrantFiled: December 10, 2009Date of Patent: October 14, 2014Assignee: Ablynx N.V.Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
-
Publication number: 20140302041Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.Type: ApplicationFiled: June 22, 2012Publication date: October 9, 2014Applicants: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140302074Abstract: The present disclosure relates generally to epitopes of an antibody known as PAT-LM1, and methods for using said epitopes.Type: ApplicationFiled: October 29, 2012Publication date: October 9, 2014Inventors: Arndt-Rene Kelter, Frank Hensel, Vic Ilag, Barbara Power, Christopher Garth Hosking
-
Publication number: 20140302049Abstract: Described herein are to antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
-
Publication number: 20140302082Abstract: A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.Type: ApplicationFiled: March 30, 2012Publication date: October 9, 2014Applicants: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASE, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, TORAY INDUSTRIES, INC.Inventors: Takaji Wakita, Tomoko Date, Yasuhito Tanaka, Masashi Mizokami
-
Publication number: 20140302048Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Applicant: Dyax Corp.Inventors: Daniel J. Sexton, Malini Viswanathan
-
Publication number: 20140302524Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: ApplicationFiled: February 4, 2014Publication date: October 9, 2014Applicant: GILEAD BIOLOGICS, INC.Inventors: Scott Alan MCCAULEY, Hector RODRIGUEZ, Carlos Aurelio GARCIA, Victoria SMITH
-
Publication number: 20140302534Abstract: The anti-canine N-terminal pro-atrial natriuretic peptide antibodies (anti-canine NT-proANP antibodies) according to the present invention comprise anti-canine NT-proANP recognizing a partial portion or a whole portion of the amino acid sequence 31 to 67 of canine NT-proANP and anti-canine NT-proANP recognizing a partial portion or a whole portion of the amino acid sequence 68 to 98 thereof. The anti-canine NT-proANP antibodies are useful for immunologically measuring canine NT-proANP involved in heart diseases and infections of companion animals such as dogs, such as heart failure, mitral valve insufficiency and filariasis. The immunochromatographic assay using the immunochromatographic means such as immunochromatographic strip is extremely convenient and simple for measuring canine NT-proANP and is used as hand-carried and simple devices.Type: ApplicationFiled: March 31, 2014Publication date: October 9, 2014Applicant: SHIBAYAGI CO., LTDInventors: Masaaki KOJIMA, Tatsuyuki HACHISU
-
Publication number: 20140301946Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140302043Abstract: The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection.Type: ApplicationFiled: February 3, 2014Publication date: October 9, 2014Applicants: DUKE UNIVERSITY, CHILDREN'S HOSPITAL BOSTONInventors: James Whittle, Stephen C. Harrison, Barton F. Haynes, Hua-Xin Liao, M. Anthomy Moody, Thomas B. Kepler, Aaron G. Schmidt
-
Publication number: 20140303020Abstract: [Problem] To provide a method for assessing myelodysplastic syndrome or myeloid tumor predisposition, on the basis of a genetic diagnosis using massively parallel sequencing technology, as well as a peptide and antibody therefor, and a method for screening for candidate therapeutic drugs or prophylactic drugs for myelodysplastic syndrome or myeloid tumor. [Solution] A method for assessing whether or not there is a predisposition for the occurrence of myelodysplastic syndrome or myeloid tumor, wherein the method comprises a step for using a sample that includes a subject's human genes and detecting a mutation in at least one gene from among the U2AF35 gene, the ZRSR2 gene, the SFRS2 gene, or the SF3B1 gene.Type: ApplicationFiled: August 2, 2012Publication date: October 9, 2014Applicant: The University of TokyoInventors: Seishi Ogawa, Masashi Sanada, Kenichi Yoshida
-
Publication number: 20140302054Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
-
Publication number: 20140302040Abstract: The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof.Type: ApplicationFiled: May 15, 2013Publication date: October 9, 2014Inventors: Satomichi Yoshimura, Tatsuya Kurihara, Kayoko Kawashima, Masato Hoshino, Kumiko Kadoshima, Maki Tsujimoto, Takako Kimura, Jun Hasegawa
-
Publication number: 20140304846Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.Type: ApplicationFiled: October 29, 2012Publication date: October 9, 2014Inventors: Sarah Elizabeth Heron, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Eileen Scheffer, John Charles Mulley
-
Publication number: 20140302511Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective of the present invention is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140301945Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: December 19, 2011Publication date: October 9, 2014Applicants: UNIVERSITY OF ZURICH, NEURIMMUNE HOLDING AGInventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan McAfoose, Marcel Maier
-
Publication number: 20140302047Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.Type: ApplicationFiled: June 19, 2014Publication date: October 9, 2014Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
-
Publication number: 20140302050Abstract: Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies.Type: ApplicationFiled: October 24, 2012Publication date: October 9, 2014Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventors: Paraic Anthony Kenny, Kelly Susan Levano Najarro, Eric Hoonee Jung
-
Publication number: 20140302045Abstract: The present invention relates to an IgY composition characterized in that said IgY composition contains IgY antibodies, fragments, and/or Fab fragments thereof that specifically bind to a peptide with the amino acid sequence of SEQ ID NO: 1 and to the use of this IgY composition in the therapy of celiac disease, rheumatism, and/or wheat allergy.Type: ApplicationFiled: March 26, 2014Publication date: October 9, 2014Applicant: CHARITE - UNIVERSITATSMEDIZIN BERLINInventor: Karl SKRINER
-
Patent number: 8853364Abstract: PSCA and its encoded protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: September 17, 2009Date of Patent: October 7, 2014Assignee: Agensys, Inc.Inventors: Wangmao Ge, Pia M. Challita-Eid, Arthur B. Raitano, Aya Jakobovits
-
Patent number: 8852871Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: GrantFiled: November 30, 2010Date of Patent: October 7, 2014Assignee: Biotest AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
-
Patent number: 8852592Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.Type: GrantFiled: May 10, 2012Date of Patent: October 7, 2014Assignee: Biocare Medical, LLCInventors: Weimin Qi, David Tacha
-
Publication number: 20140296101Abstract: The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with homology to the Mycobacterium tuberculosis hypothetical protein Rv0712, and isolated nucleic acid molecules, designated TANGO 243 nucleic acid molecules, which encode proteins with homology to human PLAP (phospholipase A2-activating protein). The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.Type: ApplicationFiled: May 2, 2014Publication date: October 2, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventor: Christopher C. Fraser
-
Publication number: 20140294845Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.Type: ApplicationFiled: February 3, 2014Publication date: October 2, 2014Applicant: GEORGETOWN UNIVERSITYInventors: J. Yun Tso, Anton Wellstein, Debra Chao
-
Publication number: 20140294819Abstract: The present invention provides acyclic polypeptide fragment of CD20 comprising (i) a contiguous amino acid sequence consisting of amino acid residues SEKNS (SEQ ID NO:67); (ii) a first cysteine residue which is present at a region N-terminal to the contiguous amino acid sequence and (iii) a second cysteine residue which is present at a region C-terminal to the contiguous amino acid sequence, wherein the cyclic polypeptide is oxidised by the presence of a disulphide bond formed between the first and second cysteine residues. Also described is the use of the cyclic peptide fragment to generate antibodies which bind specifically to CD20. Antibodies which bind specifically to the cyclic peptide fragment for use in treatment of B-cell mediated conditions in felines and canines are also described.Type: ApplicationFiled: October 12, 2012Publication date: October 2, 2014Inventor: David Gearing
-
Publication number: 20140295416Abstract: The invention relates to pharmaceutical compositions comprising of FRY polypeptides and nucleotides, methods to treat cancer, methods to diagnose cancer, and methods to determine the effectiveness of the treatment of cancer, as well as methods to differentiate stem cells.Type: ApplicationFiled: December 6, 2011Publication date: October 2, 2014Applicant: University of Medicine and Dentistry of New JerseyInventors: Helmut Zarbl, Jessica Graham
-
Publication number: 20140296492Abstract: Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.Type: ApplicationFiled: June 9, 2014Publication date: October 2, 2014Applicant: Memorial Sloan-Kettering Cancer CenterInventors: Nai-Kong CHEUNG, Dimiter Tassev, Jian Hu
-
Publication number: 20140295544Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventor: Khalid S. Abu KHABAR
-
Publication number: 20140294847Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.Type: ApplicationFiled: March 5, 2014Publication date: October 2, 2014Applicant: Ablynx N.V.Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
-
Publication number: 20140294832Abstract: Isolated monoclonal antibodies that bind to specific epitopes of human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided.Type: ApplicationFiled: March 30, 2012Publication date: October 2, 2014Applicant: BAYER HEALTHCARE LLCInventors: Zhuozhi Wang, John Murphy, Tobias Marquardt, Dieter Moosmayer
-
Publication number: 20140294731Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).Type: ApplicationFiled: October 5, 2012Publication date: October 2, 2014Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven